Open-Label Phase II Prospective, Randomized, Controlled Study of Romyelocel-L Myeloid Progenitor Cells to Reduce Infection during Induction Chemotherapy for Acute Myeloid Leukemia

120 patients with de novo acute myeloid leukemia received either romyelocel-L infusion on day nine with granulocyte colony-stimulating factor (G-CSF) starting daily on day fourteen (treatment group) or G-CSF daily alone on day fourteen (control) until absolute neutrophil count recovery to 500/µL.